Medication-overuse headache

CONTINUUM Lifelong Learning in Neurology

Volumn 18, Issue 4, 2012, Pages 807-822

  Tepper, Stewart J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BOTULINUM TOXIN A; BUTALBITAL; CAFFEINE; DEXAMETHASONE; DIHYDROERGOTAMINE; DOXEPIN; DYNORPHIN; IBUPROFEN; METHYLERGOMETRINE; METOPROLOL; NABUMETONE; NADOLOL; NAPROXEN; NARATRIPTAN; NORTRIPTYLINE; PHENOBARBITAL; PREDNISONE; PROPRANOLOL; SUMATRIPTAN; TOPIRAMATE; VALPROIC ACID; VENLAFAXINE;

ANXIETY; ARTHRITIS; BASAL GANGLION; BASILAR TYPE MIGRAINE; BEDTIME DOSAGE; BEHAVIOR THERAPY; BRAIN STEM; CAUCASIAN; CELL DAMAGE; CELL DEATH; CHRONIC DAILY HEADACHE; CIRCADIAN RHYTHM; CLINICAL FEATURE; COGNITIVE THERAPY; DEPRESSION; DIABETES MELLITUS; DRUG ABUSE; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDUCATIONAL STATUS; EPISODIC MIGRAINE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GRAY MATTER; HEAD INJURY; HOSPITALIZATION; HUMAN; LIFE EVENT; META ANALYSIS (TOPIC); NECK PAIN; NEUROTOXICITY; OBESITY; OUTPATIENT CARE; PATHOPHYSIOLOGY; PATIENT EDUCATION; PRESCRIPTION; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINORRHEA; RISK FACTOR; SLEEP DISORDER; SNORING; TRANSFORMED MIGRAINE; TREATMENT DURATION; VASOMOTOR DISORDER;

ADULT; ANALGESICS; BRAIN; GUIDELINES AS TOPIC; HEADACHE DISORDERS, SECONDARY; HUMANS; MALE; MIDDLE AGED; TRYPTAMINES;

EID: 84864877499     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/01.CON.0000418644.32032.7b     Document Type: Review

References (44)

1. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders 2nd edition. Cephalalgia 2004;24(suppl 1) 9-160.
2. Headache Classification Committee; Olesen J, Bousser M-G, Diener H-C, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006;26(6) 742-746.
3. OnabotulinumtoxinA US prescribing information, 2011. www.allergan.com/ assets/pdf/botox-pi.pdf. Published August 2011. Updated November 2011. Accessed March 6, 2012.
4. Castillo J, Mun oz P, Guitera V, Pascual J. Kaplan Award 1998. Epidemiology of chronic daily headache in the general population. Headache 1999;39(3) 190-196. (Pubitemid 29190083)
5. Scher AI, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache 1998;38(7) 497-506. (Pubitemid 28429337)
6. Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine a longitudinal population-based study. Headache 2008; 48(8) 1157-1168.
7. Lipton RB. Tracing transformation chronic migraine classification, progression, and epidemiology. Neurology 2009;72(suppl 5) S3YS7.
8. Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003; 106(1-2) 81-89. (Pubitemid 37329617)
9. Manack A, Buse DC, Serrano D, et al. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology 2011;76(8) 711-718.
10. Scher AI, Lipton RB, Stewart WF. Habitual snoring as a risk factor for chronic daily headache. Neurology 2003;60(8) 1366-1368. (Pubitemid 36460999)
11. Scher AI, Stewart WF, Lipton RB. Caffeine as a risk factor for chronic daily headache a population-based study. Neurology 2004;63(11) 2022-2027. (Pubitemid 39636246)
12. Munakata J, Hazard E, Serrano D, et al. Economic burden of transformed migraine results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache 2009;49(4) 498-508.
13. Mathew NT, Reuveni U, Perez F. Transformed or evolutive migraine. Headache 1987;27(2) 102-106. (Pubitemid 17152607)
14. Mathew NT, Kurman R, Perez F. Drug induced refractory headacheVclinical features and management. Headache 1990;30(10) 634-638.
15. Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches field trial of revised IHS criteria. Neurology 1996;47(4) 871-875.
16. Silberstein SD, Lipton RB, Solomon S, Mathew NT. Classification of daily and near-daily headaches proposed revision to the IHS criteria. Headache 1994;34(1) 1-7. (Pubitemid 24038967)
17. Warner-Schmidt JL, Vanover KE, Chen EY, et al. Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci U S A 2011;108(22) 9262-9267.
18. Fumal A, Laureys S, Di Clemente L, et al. Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain 2006;129(pt 2) 543-550. (Pubitemid 43164376)
19. Aurora SK, Barrodale PM, Tipton RL, Khodavirdi A. Brainstem dysfunction in chronic migraine as evidenced by neurophysiological and positron emission tomography studies. Headache 2007;47(7) 996-1003; discussion 1004-1007. (Pubitemid 47057220)
20. Welch KM, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine cause or the burden of illness? Headache 2001;41(7) 629-637. (Pubitemid 32777745)
21. Kruit MC, Launer LJ, Overbosch J, et al. Iron accumulation in deep brain nuclei in migraine a population-based magnetic resonance imaging study. Cephalalgia 2009;29(3) 351-359.
22. Tepper SJ, Lowe MJ, Beall E, et al. Iron deposition in pain-regulatory nuclei in episodic migraine and chronic daily headache by MRI. Headache 2012;52(2) 236-243.
23. De Felice M, Porreca F. Opiate-induced persistent pronociceptive trigeminal neural adaptations potential relevance to opiate-induced medication overuse headache. Cephalalgia 2009;29(12) 1277-1284.
24. Srikiatkhachorn A, Tarasub N, Govitrapong P. Effect of chronic analgesic exposure on the central serotonin system a possible mechanism of analgesic abuse headache. Headache 2000;40(5) 343-350. (Pubitemid 30332035)
25. Bigal ME, Lipton RB. Excessive opioid use and the development of chronic migraine. Pain 2009;142(3) 179-182.
26. Isler H. Migraine treatment as a cause of chronic migraine. In Rose FC, ed. Advances in migraine research and therapy. New York, NY Raven Press, 1982 159-164.
27. Wilkinson SM, Becker WJ, Heine JA. Opiate use to control bowel motility may induce chronic daily headache in patients with migraine. Headache 2001;41(3) 303-309. (Pubitemid 32242617)
28. Bahra A, Walsh M, Menon S, Goadsby PJ. Does chronic daily headache arise de novo in association with regular use of analgesics? Headache 2003;43(3) 179-190. (Pubitemid 36348764)
29. Kudrow L. Paradoxical effects of frequent analgesic use. Adv Neurol 1982;33 335-341.
30. Linton-Dahlö f P, Linde M, Dahlöf C. Withdrawal therapy improves chronic daily headache associated with long-term misuse of headache medication a retrospective study. Cephalalgia 2000; 20(7) 658-662. (Pubitemid 32269463)
31. Diener H-C, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine a randomized, double-blind, placebo-controlled study. Cephalalgia 2007;27(7) 814-823. (Pubitemid 46961730)
32. Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine a randomized, double-blind, placebo-controlled trial. Headache 2007;47(2) 170-180.
33. Aurora SK, Dodick DW, Turkel CC, et al; PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
34. Diener HC, Dodick DW, Aurora SK, et al; PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30(7) 804-814.
35. Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update pharmacologic treatment for episodic migraine prevention in adults report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78(17) 1337-1345.
36. Romero CE, Baron JD, Knox AP, et al. Barbiturate withdrawal following Internet purchase of Fioricet. Arch Neurol 2004;61(7) 1111-1112. (Pubitemid 38915955)
37. Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986;36(7) 995-997. (Pubitemid 16098249)
38. Drucker P, Tepper SJ. Daily sumatriptan for detoxification from rebound. Headache 1998;38(9) 687-690. (Pubitemid 28538930)
39. Krymchantowski AV, Moreira PF. Out-patient detoxification in chronic migraine comparison of strategies. Cephalalgia 2003;23(10) 982-993. (Pubitemid 37521952)
40. Diener H-C. How to treat medication-overuse headache prednisolone or no prednisolone? Neurology 2007;69(1) 14-15. (Pubitemid 47025199)
41. McLean W, Boucher EA, Brennan M, et al. Is there an indication for the use of barbiturate-containing analgesic agents in the treatment of pain? Guidelines for their safe use and withdrawal management. Canadian Pharmacists Association. Can J Clin Pharmacol 2000;7(4) 191-197. (Pubitemid 32110732)
42. Silberstein SD, McCrory D. Butalbital in the treatment of headache history, pharmacology, and efficacy. Headache 2001;41(10) 953-967. (Pubitemid 34008131)
43. Loder E, Biondi D. Oral phenobarbital loading a safe and effective method of withdrawing patients with headache from butalbital compounds. Headache 2003;43(8) 904-909. (Pubitemid 37108350)
44. Zed PJ, Loewen PS, Robinson G. Medication-induced headache overview and systematic review of therapeutic approaches. Ann Pharmacother 1999;33(1) 61-72. (Pubitemid 29056559)